Robinhood Crypto has listed the XDC token, native to the enterprise-focused XDC Network, for eligible US customers starting October 8, 2026. This allows users in most states, except some like New York, to buy, sell, and hold XDC via the Robinhood app, broadening access to a token previously limited to institutional circles. The XDC Network is a Layer-1 blockchain designed for trade finance and asset tokenization, offering fast transactions and low fees. Robinhood benefits from integration fees, adding a new revenue stream as it grows its crypto offerings.
Robinhood's listing of the XDC token provides context for cryptocurrency market activity. For readers following crypto markets, here is Pluang's market snapshot as of Oct 15, 2026 01:31 WIB: out of 50 major cryptocurrencies priced on Pluang, 6 rose and 43 fell. Notable movers include ATOM at Rp31.180 with a 1-day change of -6.12%, COTI at Rp211 with -5.48%, and UNI at Rp128.215 with -5.42%.
Jefferies has maintained a Buy rating on Big Yellow Group despite recent stock declines, citing the company's strong fundamentals including freehold properties and solid cash flows. Activist investor Ancora, holding over 4% of shares, is pushing Big ...
Fastenal reported strong Q3 2026 earnings, beating analyst expectations with EPS of $0.35 and revenue of $2.46 billion. The company saw a 20% rise in net income to $401.6 million and a 15.5% increase in revenue driven by robust manufacturing demand, ...
Remittix announced the public launch of its RTX token on November 24, 2026, marking the end of its presale phase which raised over $32 million from 40,000 participants. The project is testing its PayFi platform, which enables crypto-to-fiat and fiat-...
The global microbiology testing market is projected to grow rapidly at a compound annual growth rate (CAGR) of approximately 9% from 2026 to 2034, reaching a market size of $13.7 billion by 2034. This growth is driven by the rising prevalence of infe...
H.C. Wainwright raised its price target for Alector from $5.00 to $8.00, maintaining a Buy rating due to progress in its neurodegenerative disease pipeline. Alector develops treatments for Alzheimer's and Parkinson's using its Brain Carrier platform ...
